

1 Cost savings from managing hypertension in primary health care clinics in Kuwait

2 Ayah Odeh¹, Syed Mohamed Aljunid¹, Rihab Al-Wotayan², Mahmoud Annaka² and Mohammad Al
3 Mari¹,

4 ¹Department of Health Policy and Management, Faculty of Public Health, Kuwait University, Kuwait

5 ²Department of Primary Healthcare, Ministry of Health, Kuwait

6 Abstract

7 **Background:** Generic medications are one of the most common solutions for bringing down
8 pharmaceutical costs for both patients and health care providers. Efforts to increase uptake of generics
9 include policies to support generic substitution and prescription. The aim of this study is to estimate the
10 total cost of drugs prescribed by physicians in selected primary health care centers for managing
11 hypertension and the potential cost savings from substituting generic drugs for branded ones. **Methods**
12 **and Findings:** One thousand patients with hypertension were randomly selected from the Primary Care
13 Information System database from among patients who sought treatment at three primary health care
14 centers from Al-Jahra governorate in Kuwait from January to December 2018. Generic antihypertensive
15 drugs were substituted for branded ones, and cost savings were calculated by referring to the International
16 Drug Price Indicator Guide. The mean age of 1,000 patients was 57.01 (SD = 11.82) years. Most (57.4%)
17 of the patients were females, and 50.2% were Kuwaitis. The mean number of drugs per prescription was
18 1.78 (SD = 1.25; range: 1 to 9 drugs). The total number of drugs prescribed was 1,781, with a total cost of
19 KD 10,093 and with a mean of KD 10.09 (SD = 7.34). Only 71 generic drugs had been prescribed,
20 making the generic prescription rate 4.0%. The total number of antihypertensive drugs prescribed was
21 1,206 (mean: 1.21; SD = 0.46), with a cost of KD 7,678.5 (mean = KD 7.68; SD = 4.06) and with ACE
22 inhibitors as the most prescribed class at 32.19%. Eight hundred ninety antihypertensive drugs were
23 substituted for 774 patients at estimated cost savings of KD 5,675; that is, substituting generic drugs
24 reduced antihypertensive drug cost by 74%. **Conclusion:** Generic drug prescription appears to be low
25 among primary care physicians in health care centers in Kuwait, but these centers could see substantial
26 cost savings from substituting generic antihypertensive drugs for branded ones. Active interventions are

27 needed to encourage generic prescription among health practitioners to reduce the overall pharmaceutical
28 expenditures.

29 **Introduction**

30 Countries around the world continue to grapple with increasing health care expenditures, an
31 essential component of which are drugs [1, 2, 3] with the rise in health care costs driven mainly by
32 population growth, increasing life expectancies, and new technologies. Spending on health accounts for
33 more than 10% of gross domestic product of most developed countries, with drugs contributing to no less
34 than a fifth of health expenditures [4]. Pharmaceutical spending is growing at an average of 5.7% every
35 year, faster than other components of health expenditures [5], and the overwhelming spread of chronic
36 diseases is one of the leading causes of the rising health care costs. Patients with chronic illnesses utilize
37 more services and increase the demand for pharmaceuticals [6, 7, 8]. For these reasons, it is imperative
38 that policy makers act innovatively to control these ever-growing expenses without jeopardizing the
39 quality of care provisioned to patients.

40 Generic drugs are the most common solution for curbing pharmaceutical expenditures and
41 bringing down costs for both patients and governments. They offer the same therapeutic benefit but at
42 prices up to 80% less than the costs of originators [9]. Encouraging their uptake through generic
43 prescription and substitution has become an integral part of health care policies [10, 11, 12]. The United
44 States achieved a generic drug prescription rate (GDPR) of 90% that generated savings of up to \$265.1
45 billion [13], and the United Kingdom similarly succeeded in achieving a generic prescription rate of 84%,
46 with overall savings estimated to be £7.1 billion since 1976 attributable to generic prescription [14].
47 Furthermore, in Canada, even though generic drugs represent 73% of all drugs, they account for less than
48 20% of the total costs spent on drugs due to their low price [15]. In Kuwait, studies on generic
49 prescription rates are limited. One of the studies conducted in 2010 reported that the generic prescription
50 rate was 17.7% [16], a percentage deemed extremely low by WHO standards [17].

51 Meanwhile, as a lifelong illness, hypertension exerts a significant economic burden, especially in
52 developing countries. In the coming years, high blood pressure might cost nearly \$1 trillion globally in

53 direct health spending annually and \$3.6 trillion in indirect costs [18]. As with other chronic conditions,
54 patients with hypertension rely on health services and drugs for lifelong treatment. In Kuwait,
55 hypertension is one of the most debilitating diseases, ranking as the sixth leading cause of death in the
56 country at 37% of all deaths [19]. With 27.8% of Kuwait's population estimated to be suffering from
57 hypertension that requires prolonged treatment [19], reducing the cost of antihypertensive drugs could
58 translate to remarkable savings during patients' lifetime. Hence, in this study, we sought to determine the
59 rate of generic drug prescription among primary health care physicians in Kuwait and to estimate the total
60 cost of drugs prescribed for hypertension management as well as the potential cost savings from
61 substituting generic antihypertensive drugs for branded ones.

62 **Methods**

63 **Study design, sampling determination, and source of data**

64 We conducted this cross-sectional study in three primary health care clinics (PHCCs) located in
65 Al-Jahra governorate in Kuwait. We searched the Primary Care Information System database of patients
66 using the inclusion criteria of a diagnosis with hypertension and prescriptions for antihypertensive drugs
67 from January to December 2018. Excluding patients without hypertension or with incomplete drug
68 information, we selected the first 1,000 patients as the sample for this study after we randomly assigned
69 them using Microsoft Excel's random number function and arranged the numbers in descending order.
70 We used the previously reported PHCC GDPR for Kuwait of 17.7% [16] to estimate the sample size and
71 used OPENEPI to calculate that a minimum of 224 patients were required, but we selected a sample of
72 1,000 patients to compensate for the lower GDPR in the benchmarked study. We also gathered the
73 patients' demographic data, diagnoses, and drugs from the Primary Care Information System, ascertaining
74 what drugs had been chosen for substitution from the list of antihypertensive agents in the *2017 Report of*
75 *the American College of Cardiology/American Heart Association Task Force on Clinical Practice*
76 *Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.*

77 **Data management procedures**

78 We obtained public prescription prices from the Drug Price List for January 2020 released by the
79 Kuwaiti Ministry of Health's (MOH) Pharmaceutical & Herbal Medicines Registration & Control
80 Administration, excluding drugs and other pharmaceutical preparations listed without prices. To calculate
81 the cost of antihypertensive drugs for our analyses, we standardized the treatment duration to one month.
82 We calculated the defined daily dose based on the usual adult maintenance dose for managing
83 hypertension [20]. Hence, the price for one month was as follows: defined daily dose (DDD) \times 30 days \times
84 unit price = price in KD/month/drug [21]. For non-antihypertensive drugs, we assumed the cost of one
85 pack except for Vitamin D3 50,000 IU, the cost of which we calculated based on the dosage of one unit
86 per week for a month. We reviewed all prescriptions to identify drugs that had been prescribed as generic
87 or by brand name to calculate the GDPR, which we calculated by dividing the number of generic drugs
88 prescribed by the total number of drugs prescribed.

89 For the substitutions of generic antihypertensive drugs, we used prices from the *International*
90 *Drug Price Indicator Guide 2015*, released by the Management Sciences for Health, Inc., in collaboration
91 with the WHO [22] using the median buyer price/unit. We used the same method to calculate the costs of
92 the originally prescribed drugs along with factoring in shipping costs, inflation rate, and USD conversion
93 rate: DDD \times median unit price from guide \times 30 days \times 10% shipping \times inflation rate \times conversion rate =
94 price in KD/month/generic drug. The guide provides generic prices only for essential medications, and as
95 such, we could not substitute all antihypertensive drugs that the physicians at the three PHCCs that we
96 studied had prescribed for their patients. Ultimately, we imputed three main costs for analysis: the total
97 cost of the prescriptions, the cost of antihypertensive drugs, and the amount of savings generated by
98 generic substitution.

99 **Statistical analysis**

100 We analyzed the study data using Statistical Package for Social Sciences, version 24, with
101 significance set at 5%. Categorical variables were summarized using frequencies and proportions, and
102 continuous variables were summarized using means and standard deviation, and medians and interquartile

103 ranges. We also used the Mann–Whitney U test to compare the medians of the total prescription costs
104 before and after generic substitution.

105 **Ethical Approval**

106 The study was approved by the Research and Ethics Committee in the Health Sciences Center,
107 Kuwait University and the Standing Committee for coordination of health and medical research in the
108 Ministry of Health.

109 **Results**

110 **Patient demographics**

111 In a random sample of 1,000 patients with hypertension, more than half of patients (57.4%) were
112 female, and there were slightly more Kuwaiti (50.2%) than non-Kuwaiti (49.8%) patients. The mean age
113 of patients was 57.01 years (SD = 11.82), and the median was 56 years. Most of the patients were in the
114 age group of 45 to 64 (61.2%), and elderly patients (65 and above) represented only 24.5% of the sample.
115 The duration of illness was only available for 461 patients and had a mean of 11.11 (SD = 5.8) years
116 (Table 1).

117 **Table 1. Clinical and Sociodemographic Profile of Patients.**

Characteristic	Number of patients (%)
Gender	
Female	574 (57.4%)
Male	426 (42.6%)
Age (mean ± SD)	57.01 ± 11.82
Below 45 years	143 (14.3%)
45–64 years	612 (61.2%)
65 and above	245 (24.5%)
Nationality	
Kuwaiti	502 (50.2%)
Non-Kuwaiti	498 (49.8%)
Duration of illness	
Less than 5 years	79 (17.1%)
5–9 years	106 (23.0%)
More than 9 years	276 (59.9)
Total	461 (100%)
Mean 11.11 ± 5.81	

118

119 **Drug prescriptions**

120 The total number of drugs prescribed for the 1,000 patients was 1,781, with a mean number of
121 drugs prescribed per prescription of 1.78 (SD = 1.25) and a median of 1. Over half (60.4%) of the patients
122 had been prescribed one drug per visit. Table 2 presents the data on drugs distributed to patients in this
123 study.

124 **Table 2. Distribution of Drugs Prescribed to Patients.**

Number of drugs per prescription	Number of patients (%)
1	604 (60.4%)
2	187 (18.7%)
3	106 (10.6%)
4	63 (6.3%)
5	22 (2.2%)
6 and above	18 (1.8%)
Total	1,000 (100%)

125
126 Providers at the three PHCCs in this study prescribed a total of 71 generic drugs to 56 patients,
127 making the generic prescription rate 4.0%. The average number of generic drugs was 0.07 (SD = 0.32),
128 with a median of 0, whereas the average number of branded drugs was 1.71 (SD = 1.14), with a median of
129 1 (Table 3).

130 **Table 3. Distribution of Branded and Generic Drugs.**

Type of drug prescribed	Number of drugs (%)
Generic	71 (4.0%)
Branded	1,710 (96.0%)
Total	1,781 (100%)

131

132 The number of antihypertensive drugs prescribed in this study was 1,206, averaging 1.21 (± 0.46)
133 per patient, with a median of 1. Most patients (81.7%) had been prescribed only one antihypertensive
134 drug (Table 4).

135 **Table 4. Distribution of Antihypertensive Drugs among Patients.**

Number of antihypertensive drugs	Number of patients (%)
1	817 (81.7%)
2	160 (16.0%)
3	23 (2.3%)
Total	1,000 (100%)

136
137 The most prescribed class of antihypertensive drugs was angiotensin-converting enzyme
138 inhibitors (ACEIs), representing 32.2%, followed by calcium channel blockers (CCBs), beta blockers
139 (BBs), and angiotensin ii receptor blockers (ARBs). Tables 5 and 6 present the generic antihypertensive
140 drugs prescribed by type and the branded antihypertensive drugs prescribed, respectively.

141 **Table 5. List of Generic Antihypertensive Drug Types Prescribed.**

Antihypertensive drugs prescribed by brand name	Number (%)
Alpha-blockers & receptor agonists	10 (0.8%)
ACEIs	385 (32.2%)
ARBs	126 (10.6%)
BBs	136 (11.4%)
CCBs	182 (15.2%)
Centrally acting antiadrenergic	59 (4.9%)
Combination drugs	254 (22.0%)
Diuretics	44 (4.0%)
Total	1,196 (100%)

142 **Table 6. List of Branded Antihypertensive Drugs Prescribed.**

Antihypertensive drugs prescribed by generic name	Number (%)
Amlodipine	1 (10%)
Captopril	2 (20%)
Cilazapril	3 (30%)
Clindipine	1 (10%)
Losartan	1 (10%)
Valsartan	2 (20%)
Total	10 (100%)

143

144 **Drug costs**

145 The overall cost of drugs for all 1,000 patients was KD 10,092.99, with a mean of KD 10.09 (SD
146 = 7.34) and a median of KD 8.06. Most patients' prescriptions (83%) cost less than KD 15. Tables 7 and
147 8 present the data on the overall and hypertensive drug costs and the distributions among the patients.

148 **Cost of antihypertensive drugs**

149 The total cost of antihypertensive drugs was KD 7,678.49, representing 76% of the total cost of
150 all prescriptions. The average cost of antihypertensive drugs was KD 7.68, and more than a third (40.2%)
151 of the antihypertensive drugs cost less than KD 10.

152 **Amount of cost savings**

153 The total amount of savings achieved by substituting generic antihypertensive drugs for branded
154 drugs for 774 patients was KD 5,675.04. Substituting 890 antihypertensive drugs (73.8%) reduced total
155 prescription costs by 56.2% and total antihypertensive drug costs by 73.9%.

156

157

158

159 **Table 7. Drug Costs for 1,000 Patients.**

Cost	Total (KD)	Mean	SD	Median	IQR	Mode
Total cost of prescription	10,092.99	10.09	7.34	8.06	6.38	8.06
Cost of antihypertensive drugs	7,678.49	7.68	4.06	7.16	5.73	11.76
Cost of prescription after generic substitution	4,417.97	4.42	6.53	2.13	3.24	0.56
Cost of antihypertensive drugs after generic substitution	2,003.47	2.00	2.26	0.91	3.24	0.56
Amount of cost saving	5,675.04	5.68	4.32	5.19	7.81	0

160

161 **Table 8. Drug Cost Distribution among Patients.**

Cost (KD)	Number of patients (%)		
	Cost of prescription	Cost of antihypertensive drugs	Amount of savings
Less than 5.00	247 (24.7%)	312 (31.2%)	227 (22.7%)
5.00–9.99	364 (36.4%)	402 (40.2%)	232 (23.2%)
10.00–14.99	219 (21.9%)	244 (24.4%)	294 (29.4%)
15.00 and above	170 (17%)	42 (4.2%)	247 (24.7%)
Total	1,000 (100%)	1,000 (100%)	1,000 (100%)

162

163 **National cost savings**

164 The prevalence of hypertension in Kuwait is estimated to be 27.8% [19]. On the basis of this
 165 prevalence, we attempted to calculate national savings from substituting 22 types of antihypertensive
 166 drugs in Kuwait. Table 9 presents our findings.

167

168 **Table 9. National Savings from Generic Substitution of Generic Antihypertensive Drugs.**

Prevalence of hypertension	27.8%
Population of Kuwait in 2019	4.7 million
Median amount of saving/month/patient	5.187
Number of people with hypertension	4.7 million × 27.8% = 1,306,600
Amount saved for hypertension population/year	1.3 million × 5.187 × 12 = KD 81,328,010

169

170 To check the robustness of the results, we conducted a sensitivity analysis. We calculated the

171 savings for prevalence rates 10% lower and 10% higher than the actual prevalence and for generic

172 substitution rates 26% above and below the actual substitution rates, representing the best and worst-case

173 scenarios respectively. Table 10 presents the best- and worst-case scenario sensitivity analysis findings.

174 **Table 10. National Savings from Substituting Generic Hypertensive Drugs for Brand Name.**

Component	Savings (KD)
17.8% prevalence and 100% substituted (Best case)	70,274,400
27.8% prevalence and 74% substituted (Base)	81,328,010
37.8% prevalence and 48% substituted (Worst case)	71,739,108

175

176 **Discussion**

177 The main findings of this study are a low GDPR and a promising amount of savings achieved by

178 substituting generic antihypertensive drugs for branded drugs. The majority of the patients were below 64

179 years of age, even though previous researchers have well established that hypertension prevalence in

180 Kuwait [23] and worldwide increases with age, especially after 60 [24]. However, these numbers could

181 merely reflect the governorate's age distribution: in recent statistics, elderly citizens above age 65

182 represented only 2.1% of Al-Jahra's inhabitants and 98% were below 64 years [25]. In 1980, hypertension

183 prevalence among Kuwaiti nationals and non-nationals was 8.3% in men and 12.9% in women, and in

184 1999, the prevalence among Kuwaitis only was reported to be 28.3% in men and 22.9% in women [23].
185 In this study, the sample had more female than male patients, and in a previous study, on drug compliance
186 among patients with hypertension visiting primary health care clinics, female participants also
187 outnumbered males (59.8% to 40.2%) [26].

188 The GDPR in this study was 4.0%, lower than the rate of 14.7% previously reported in Al-Jahra
189 governorate primary health care clinics, and the median number of drugs per prescription was also lower
190 than the previously reported median of 2.6 [16]. These differences, however, could be attributed to the
191 different methodologies in selecting patients. The previous study's authors included prescriptions for
192 general illnesses but excluded chronic diseases such as hypertension, whereas in this study, we studied
193 only patients with hypertension. The objectives of the two studies were different, hence the different
194 inclusion criteria and accompanying differing results.

195 That being said, both the GDPRs reported in Kuwait in 2010 and in this study are low by WHO
196 standards. Ideally, 100% of prescriptions are for generic versions [17]. The rates in the neighboring Gulf
197 countries of Kingdom of Saudi Arabia, Bahrain, and United Arab Emirates (2.9%–19.5%, 14.3%, and
198 7.4%, respectively) are similarly low [16]. In the UK, the GDPR is 84% [14], and in the United States, it
199 is nearly 90% [13].

200 In 2010, the low generic prescription rate was attributed to the feature of the primary health care
201 electronic system that it only showed drugs by their brand names [16]. This system has since been
202 updated to include both generic international non-propriety and brand names of drugs, and even with that
203 change, prescription by generic names actually decreased. Until recently, the MOH had no official
204 requirement that physicians prescribe generic drugs. Not until January 25, 2020, did a new ministerial
205 decree oblige physicians to prescribe medications by their generic non-propriety names [27].

206 Furthermore, physicians in Kuwait do not receive adequate training on hospital supply
207 management, despite their having a key role in selecting treatments. Instead, they base their decisions
208 regarding pharmaceuticals on personal opinion, training, and relationships formed with pharmaceutical
209 companies through drug company representatives and sponsored conventions but without regard to cost.

210 In turn, drug companies encourage their representatives to build strong relationships with physicians
211 through value-added services to influence their prescription [28]. Moreover, because physicians often
212 encounter brand names of drugs during their training, they are more likely to remember these drugs [16].
213 Therefore, educating physicians on the basics of health care supply management, such as informing them
214 of prices and the potential savings from substituting generics, can help in promoting generic drug
215 prescription in Kuwait.

216 Moreover, the MOH should have physicians receive their medication information from academics
217 rather than medical company representatives. Researchers established that in contrast to detailing by
218 medical representatives, academic detailing had a positive influence on physicians' prescription habits
219 that had relied on presenting neutral and evidence-based drug information [29]. The ministry could
220 organize regular interactive sessions led by experts to supply physicians with information on prescription
221 drugs uses.

222 In addition, although the MOH has the unofficial policy of allowing pharmacists to switch drug
223 brands according to their availability, the availability of generics in Kuwait is limited, restricting
224 pharmacists' ability to substitute [30]. In this study, nearly all of the antihypertensive drugs prescribed
225 had been branded ones, and the generic drugs prescribed were mainly vitamins, supplements, and
226 antibiotics, but drugs used to treat chronic diseases were prescribed mostly by brand name, perhaps
227 reflecting drug companies' marketing focus on the chronic "diseases of the century" and the drugs to treat
228 them that hold the biggest share of the pharmaceutical market. Furthermore, the five most-prescribed
229 antihypertensive drugs by brand name were all originator-branded drugs that have generic versions on
230 international markets and were among the highest-costing drugs, indicating an opportunity for cost saving
231 by substituting generics.

232 Kuwait has a high per capita income, which means the demand for quality in health care is high,
233 but the limited indigenous manufacturing capabilities of pharmaceuticals led to dependence on imported
234 pharmaceuticals. In 2017, originator drugs led the pharmaceutical market sales in Kuwait, and generic
235 drug market penetration was limited [31]. In 2019, generics made up only 21.6% of the Kuwaiti

236 pharmaceutical market, in contrast to UK and USA where generic prescriptions are as high as 89% and
237 81%, respectively [28]. People usually equate high cost with high quality, which has popularized more
238 expensive branded medications over generics and reduced demand for them. Additionally, the high per
239 capita income of most of the Kuwaiti population has led to low patient acceptance of generic drugs [32].
240 Patients with chronic diseases are accustomed to taking more expensive branded drugs, and they might
241 refuse generic versions for a variety of reasons such as misconceptions regarding their quality. For
242 instance, authors of one study found conflicting opinions on generic and branded medications among
243 patients with diabetes in Kuwait, with some believing that generics were less effective and had more side
244 effects than foreign brands [33]. In another study, in countries where reliance on the public health sector
245 is predominant, patients are more likely to demand the costliest treatments. Patients are aware that generic
246 drugs cost less, but they demand the branded versions because they do not bear the costs [28], which
247 raises the issue of educating patients on the bioequivalence of generics to increase their acceptability.
248 New terms and specifications for the purchase and sale of generic medications in Kuwait were approved
249 back in October 2019, and the MOH has also decided that generic medications will constitute 20% of all
250 medications in Kuwait and branded ones will represent 80% [34,35].

251 During the time period that we studied (January to December 2018), most patients with
252 hypertension had been prescribed one antihypertensive drug, and only 2.3% had been prescribed three
253 drugs. In the Middle East, 40.5% of patients received two drugs for hypertension, and only 23.5% were
254 on monotherapy [36]. In one study in Saudi Arabia, 48.9% of patients received one antihypertensive drug,
255 31% received two, and 23.3% received three or more [37], and results were similar in a study in Bahrain.
256 Most patients in the latter study (62.9%) were treated with monotherapy [38]. In Jordan, 46.2% of patients
257 with hypertension in one study received one drug for managing hypertension, and only 15.6% received
258 three or more drugs [39]. By contrast, in the United States, most patients with hypertension receive
259 multiple drugs to achieve better control [40].

260 In this study, angiotensin-converting enzyme inhibitors were the most prescribed class of
261 antihypertensive agents, and of the drugs prescribed, the originator-brand ACEIs and ARBs were among

262 the costliest. In 1999, the Central Medical Stores had BBs as the top-consumed drugs at 44.7%, followed
263 by ACEIs at 16.9%, centrally acting agents at 13.3%, CCBs at 12.5%, diuretics at 12%, vasodilators at
264 0.3%, and alpha-blockers at 0.2% [23]. These numbers reflected the whole country's consumption,
265 including primary health care clinics, although ARBs were just newly introduced in Kuwait and as such
266 were not included in the calculations [23]. In previous years, ACEI prescription increased, and indeed,
267 ACEIs were the most prescribed in this study (32.19%). Among the ACEIs, lisinopril was the most
268 prescribed (37.2%), which was also the case in 1999 [23]. Lisinopril is also the most widely used ACEI in
269 the United States [40].

270 In this study, ACEIs accounted for almost half of the total prescription cost, and the major ACEIs
271 prescribed were all originator drugs. Gradual shifts to the use of generic drugs could begin with ACEIs
272 given that they are prescribed the most and cost the most. The second category worth considering for
273 substitution could be CCB. Analysis of the combination drugs revealed that ARBs were prescribed more
274 than CCBs but that CCBs represented 13% of the antihypertensive drug costs whereas ARBs represented
275 only 10%. ACEIs and CCBs are known to be among the most expensive antihypertensive drugs [41]. For
276 instance, in Bahrain in one study, the cost of ACEIs represented two-thirds of the antihypertensive drug
277 costs even though they were not the most widely used [38].

278 The US Association for Accessible Medicines reported that the CCB Norvasc (generic name:
279 amlodipine) showed savings of USD 5.7 billion when the generic was substituted, drug savings that
280 ranked among the top 10 [13]. To the best of our knowledge, no previous researchers in Kuwait aimed to
281 impute the amount of savings that could be derived from substituting generic antihypertensive drugs for
282 their branded originals in primary care centers. In the only study we are aware of, Cameron et al.
283 estimated the amount of savings from substituting generics in a number of developing countries, and
284 savings were lowest in Kuwait at 9% (int\$ 44,785 = KD 13,778.11) [42]. The savings came from
285 switching six drugs, two of which are antihypertensive drugs included in this study (captopril 25 mg and
286 atenolol 50 mg), and the low savings were attributed to the low difference between the prices of the
287 branded drugs and their equivalent generics [42]. In that study, generics cost more in Kuwait than in other

288 countries, and innovator drugs were purchased from 1.2 to 32.9 times the international reference prices
289 and generics from 0.1 to 22.2 times the international prices [42].

290 The low number of generics in Kuwait resulted in the absence of the competition that usually
291 drives down drug prices. However, the MOH Pricing Department has been recently adjusting drug prices
292 to account for drugs going off patent and taking into account prices in the region, and as such, it could be
293 worthwhile to repeat this price study in the future to assess if higher savings could be achieved.
294 Substituting a total of 890 antihypertensive drugs for 774 patients reduced total antihypertensive drug
295 costs by 73.9%, with an average savings of KD 5.68. The 890 drugs substituted corresponded to 22
296 branded drugs. With an estimated 27.8% of the population living with elevated blood pressure, we
297 estimate that Kuwait could achieve national cost savings of KD 81,328,010.4 per year for all patients with
298 hypertension, and the sensitivity analysis showed that savings in the case of a lower prevalence of
299 hypertension could still be significant.

300 Al Kanderi et al. 2009 reported in their study that there was a lack of essential antihypertensive
301 drugs in primary health care clinics in Kuwait. According to the authors, MOH's policy of confining
302 expensive drugs to secondary and tertiary hospitals had likely driven overreliance on these facilities,
303 where the increasing costs of antihypertensive drugs had made them unavailable in primary healthcare
304 centers [43]. Higher costs and drug unavailability can lead to patient noncompliance with therapy and to
305 uncontrolled hypertension, eventually increasing future health care expenditures due to complications
306 [26]. Patients with hypertension often rely on primary health care clinics to regularly check their blood
307 pressure and receive their monthly prescriptions, which is why it could be worthwhile to find a solution to
308 this problem, such as switching to lower-priced generic drugs. Reducing the cost of antihypertensive
309 drugs could increase their availability in primary health care clinics, reducing the pressure on secondary-
310 and tertiary-level hospitals and increasing patient adherence to drug therapies.

311 Kuwait provides treatment free of charge to its citizens and at a subsidized cost for residents, so
312 the government bears the cost of expensive drug brands. With the aging population and increases in non-
313 communicable diseases, the price differences between branded and generic drugs should not be

314 considered trivial. Even with low-cost medications, cost differences between generic and branded drugs
315 in chronic diseases could translate into thousands of Kuwaiti dinars saved over a given patient's life. Non-
316 communicable diseases require recurrent and long-term medication services. In particular, cardiovascular
317 diseases and hypertension take up a significant amount of total government health expenditures even as
318 fewer persons might be affected as by other diseases. Cardiovascular diseases require frequent outpatient
319 visits and expensive interventions, they result in intensive care unit admissions, and they are also
320 associated with lengthier hospital stays and work absenteeism [23]. The MOH's reliance on mostly
321 innovator-branded drugs is unnecessary, and the potential savings from increasing the generic penetration
322 in the Kuwaiti market are still untapped [30].

323 **Limitations**

324 We encountered several challenges in the course of this study. Only three primary care centers
325 were made available to be sampled, and all were from one governorate in Kuwait. Generalizing the
326 current study findings will require a more representative sample from PHCCs across multiple regions of
327 Kuwait. Moreover, we were forced to use the 2015 International Medical Products Price Guide when
328 substituting generic drugs owing to the limited availability of generic drugs in Kuwait.

329 **Conclusion**

330 Many countries have followed the recommendations of the WHO in promoting the use of generic
331 drugs as a means of bringing down pharmaceutical expenditures and increasing access to medications.
332 Kuwait has recently joined other countries in mandating prescription by generic name and increasing the
333 availability of generics in the Kuwaiti pharmaceutical market, yet the generic prescription rate is still low.
334 With the increasing prevalence of hypertension and its status as a lifelong illness came a necessity for
335 decreasing its cost of treatment. With this study, we aimed to analyze the cost of drugs for managing
336 hypertension in selected primary health care centers in Kuwait and to calculate the amount of savings that
337 could be generated by substituting generic antihypertensive drugs for their branded equivalents. As we
338 expected, only 71 generic drugs had been prescribed, making the generic prescription rate 4.0%, a rate the
339 WHO considers very low. However, even at this low rate, substituting 890 antihypertensive drugs

340 reduced total prescription costs by 56.23% and total antihypertensive drug costs by 73.91%, a promising
341 amount that is in line with reports that prices of generics are anywhere between 10% and 90% less than
342 those of originator drugs.

343 For this study, we estimated the national savings by assuming that all 1,306,600 patients with
344 hypertension were treated in the same manner at the expense of the government, which carries the risk
345 that we overestimated the savings. However, we did show that even for just one chronic condition,
346 hypertension, the savings generated by substituting generic drugs for their originator brands could be
347 significant enough to warrant policy changes. Barriers persist in Kuwait to the successful implementation
348 of policies that encourage generic prescription, including the absence of national drug policy, the negative
349 perception of the quality of generics, the heavy dependence on imported drugs, and the limited
350 availability of generics in the Kuwaiti pharmaceutical market. These need to be addressed if Kuwait is to
351 achieve a similar generic prescription rate to those reported by most developed countries.

352 **Acknowledgments**

353 Our deepest gratitude for the Primary Healthcare Division of MOH for acquiring the data that made this
354 research possible. Our special thanks is offered to Dr. Donia AlBastaki, Head of the Drug Registration
355 Department for providing information essential for the progress of this research. The authors would also
356 like to thank Enago (www.enago.com) for the English language review.

357 **Author contributions**

358 Concept and design: AO and SA were responsible for conceptualizing and designing the study. AO, SA,
359 RA and MA² were involved in acquisition of the data. AO & SA performed the analysis of the data. AO,
360 SA and MA¹ carried out the drafting of the manuscript. SA undertook critical revisions of the manuscript
361 for important intellectual content.

362 **Declaring conflict of interest**

363 None declared.

364 **Funding**

365 No funding was received.

366 **References**

- 367 1. Newman-Casey PA, Woodward MA, Nizioł LM, Lee PP, De Lott LB. Brand medications and
368 Medicare Part D: how eye care providers' prescribing patterns influence costs. *Ophthalmology*. 2018;125: 332-
369 339.
- 370 2. Ali Jadoo SAA, Aljunid SM, Nur AM, Ahmed Z, Van Dort D. Development of MY-DRG casemix
371 pharmacy service weights in UKM Medical Centre in Malaysia. *DARU J Pharm Sci*. 2015;23: 14.
- 372 3. Sudhanthar, S., Turner, J., Thakur, K. and Sigal, Y. (2015). Improving viable low cost generic
373 medication prescription rate in primary care pediatric practice. *BMJ Quality Improvement Reports*, 4(1),
374 pp.u209517.w3931.
- 375 4. OECD. Health resources - Pharmaceutical spending - OECD Data. 2019. [Cited 2019 Mar 29].
376 Available from: <https://data.oecd.org/healthres/pharmaceutical-spending.htm>
- 377 5. OECD. Health at a glance 2011: OECD indicators. Paris: OECD Publishing; 2011.
- 378 6. Deloitte. Global health care sector outlook. Deloitte. 2019; 2019.. [Cited 2019 March 29]. Available
379 from: [https://www2.deloitte.com/global/en/pages/life-sciences-and-healthcare/articles/global-health-care-](https://www2.deloitte.com/global/en/pages/life-sciences-and-healthcare/articles/global-health-care-sector-outlook.html)
380 [sector-outlook.html](https://www2.deloitte.com/global/en/pages/life-sciences-and-healthcare/articles/global-health-care-sector-outlook.html)
- 381 7. William 44. Russell W. What is driving up the cost of global healthcare? | William Russell. 2017.
382 [Cited 2019 March 29]. Available from: [https://www.william-russell.com/blogs/driving-cost-global-](https://www.william-russell.com/blogs/driving-cost-global-healthcare/)
383 [healthcare/](https://www.william-russell.com/blogs/driving-cost-global-healthcare/).
- 384 8. Investopedia. Why do healthcare costs keep rising? 2018. Available from:
385 <https://www.investopedia.com/insurance/why-do-healthcare-costs-keep-rising>.
- 386 9. Docteur E, Paris V. Ensuring efficiency in pharmaceutical expenditures. In: OECD, achieving better
387 value for money in health care. OECD Publishing; 2009.
- 388 10. Mathew P. Generic drugs: review and experiences from South India. *J Fam Med Prim Care*. 2015;4:
389 319–323.
- 390 11. Liberman JN, Roebuck MC. Prescription drug costs and the generic dispensing ratio. *J Manag Care*
391 *Pharm*. 2010;16: 502-506.

- 392 12. Hassali MA, Alrasheedy AA, McLachlan A, Nguyen TA, AL-Tamimi SK, Ibrahim MI, et al. The
393 experiences of implementing generic medicine policy in eight countries: a review and recommendations for a
394 successful promotion of generic medicine use. *Saudi Pharm J.* 2014;22: 491-503.
- 395 13. Association for Accessible Medicines. Generic drug access & savings in the U.S. Washington:
396 Accessible Medicines. 2018 [Cited 2019 April 22]. Available from:
397 https://accessiblemeds.org/sites/default/files/2018_aam_generic_drug_access_and_savings_report.pdf
- 398 14. The King's Fund. How much has generic prescribing and dispensing saved the NHS? 2019. [Cited
399 2019 April 22]. Available from: [https://www.kingsfund.org.uk/blog/2015/07/how-much-has-generic-](https://www.kingsfund.org.uk/blog/2015/07/how-much-has-generic-prescribing-and-dispensing-saved-nhs)
400 [prescribing-and-dispensing-saved-nhs.](https://www.kingsfund.org.uk/blog/2015/07/how-much-has-generic-prescribing-and-dispensing-saved-nhs)
- 401 15. Prices of Canadian generic medicines Below international average – Canadian generic pharmaceutical
402 association. *Canadiangenerics.ca.* 2020). [Cited 2020 Sep4], Available from: [https://canadiangenerics.ca/news-](https://canadiangenerics.ca/news-release622/prices-of-canadian-generic-medicines-below-international-average/)
403 [release622/prices-of-canadian-generic-medicines-below-international-average/.](https://canadiangenerics.ca/news-release622/prices-of-canadian-generic-medicines-below-international-average/)
- 404 16. Awad A, Al-Saffar N. Evaluation of drug use practices at primary healthcare centers of Kuwait. *Eur J*
405 *Clin Pharmacol.* 2010;66: 1247-1255.
- 406 17. Ofori-Asenso R. A closer look at the World Health Organization's prescribing indicators. *J Pharmacol*
407 *Pharmacother.* 2016;7: 51–54.
- 408 18. Gaziano TA, Bitton A, Anand S, Weinstein MC, International Society of Hypertension. The global
409 cost of nonoptimal blood pressure. *J Hypertens.* 2009;27: 1472-1477.
- 410 19. Kuwait. Institute for Health Metrics and Evaluation. (2020). Retrieved 14 June 2020, from
411 [http://www.healthdata.org/kuwait.](http://www.healthdata.org/kuwait)
- 412 20. Drugs.com. Prescription Drug Information, Interactions & Side Effects. Available from:
413 <https://www.drugs.com/>; 2021.
- 414 21. Defined daily dose (DDD). Available from: [https://www.who.int/medicines/regulation/medicines-](https://www.who.int/medicines/regulation/medicines-safety/toolkit_ddd/en/)
415 [safety/toolkit_ddd/en/.](https://www.who.int/medicines/regulation/medicines-safety/toolkit_ddd/en/) World Health Organization; 2020.
- 416 22. International medical products price guide. 2015. Available from: [http://mshpriceguide.org/wp-](http://mshpriceguide.org/wp-content/uploads/2017/04/MSH-2015-International-Medical-Products-Price-Guide.pdf)
417 [content/uploads/2017/04/MSH-2015-International-Medical-Products-Price-Guide.pdf.](http://mshpriceguide.org/wp-content/uploads/2017/04/MSH-2015-International-Medical-Products-Price-Guide.pdf)

- 418 23. El-Reshaid K, Al-Owaish R, Diab A. Hypertension in Kuwait: the past, present and future. Saudi J
419 Kidney Dis Transpl. 1999; 10: 357-364. [Cited 2020 Sep 3]. Available from:
420 <http://www.sjkdt.org/text.asp?1999/10/3/357/37244>.
- 421 24. Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension prevalence and control
422 among adults: United States, 2015–2016. NCHS Data Brief. Hyattsville, MD: National Center for Health
423 Statistics. 2017. Available from: <https://www.cdc.gov/nchs/data/databriefs/db289.pdf>;289: 1–8.
- 424 25. Al-Jahrā'(Governorate, Kuwait) - Population Statistics, Charts, Map and Location. (2020)
425 Citypopulation.de. [Cited 2020 June 15]. Available from:
426 https://www.citypopulation.de/en/kuwait/admin/4__al_jahr%C4%81/.
- 427 26. Al-Mehza AM, Al-Muhailije FA, Khalfan MM, Al-Yahya AA. Drug Compliance Among
428 Hypertensive Patients; an Area Based Study. Electron J Gen Med. 2009;6: 6-10.
- 429 27. Ministry of Health. MOH obliges doctors with generic prescribing. Kuwait: Health Media Office;
430 2020.
- 431 28. Abdulsalam Y. The role of doctors in Kuwait's healthcare costs. LSE Middle East Centre Paper
432 Series. 29. London, UK: LSE Middle East Centre; 2019.
- 433 29. Sarpatwari A, Choudhry NK, Avorn J, Kesselheim AS. Paying physicians to prescribe generic drugs
434 and follow-on biologics in the United States. PLOS Med. 2015;12: e1001802.
- 435 30. Ball D, Tisocki K, et al. Saffar, N. Medicine Prices, availability, affordability and price components,
436 Kuwait. 2009. Available from: [http://haiweb.org/wp-content/uploads/2015/07/Kuwait-summary-report-](http://haiweb.org/wp-content/uploads/2015/07/Kuwait-summary-report-pricing-surveys.pdf)
437 [pricing-surveys.pdf](http://haiweb.org/wp-content/uploads/2015/07/Kuwait-summary-report-pricing-surveys.pdf).
- 438 31. Ken Research Private Limited. Kuwait Pharmaceuticals Market Outlook to;2022 - . By type of drugs;
439 by channel of distribution and by therapeutic class. 2018. Available from:
440 <https://www.researchandmarkets.com/reports/4769096/kuwait-pharmaceuticals-market-outlook-to-2022#pos->
441 0.
- 442 32. Al-Junid SM, Ezat WP, Surianti S. Prescribing patterns and drug cost among cardiovascular patients
443 in Hospital Universiti Kebangsaan Malaysia. Med J Malaysia. 2007;62: 59–65.

- 444 33. Jeragh-Alhaddad FB, Waheedi M, Barber ND, Brock TP. Barriers to medication taking among
445 Kuwaiti patients with type 2 diabetes: a qualitative study. *Patient Preference Adherence*. 2015;9: 1491–1503.
- 446 34. Arab Times. Kuwait approves purchase and sale of drugs. 2019 [Cited 2020 March 17]. Available
447 from: <https://www.arabtimesonline.com/news/kuwait-approves-purchase-and-sale-of-generic-drugs/>.
- 448 35. Kuwait News Agency. Kuwait MOH oks generic drugs. 2019. [Retrieved 17 March 2020] Available
449 from: <https://www.kuna.net.kw/ArticleDetails.aspx?id=2824501&Language=enKuwait>.
- 450 36. Bramlage P, Böhm M, Volpe M, Khan BV, Paar WD, Tebbe U, et al. A global perspective on blood
451 pressure treatment and control in a referred cohort of hypertensive patients. *J Clin Hypertens (Greenwich)*.
452 2010;12: 666-677.
- 453 37. Al Duraihim H, Alghamdi G, AlNemer M, Abdulaal AE, Al Sayyari A. Blood pressure control,
454 lifestyle and disease awareness of Saudi hypertensive patients. *Saudi J Kidney Dis Transpl*. 2019;30: 33-38.
- 455 38. Jassim Al Khaja KA, Sequeira RP, Wahab AW, Mathur VS. Antihypertensive drug prescription trends
456 at the primary health care centres in Bahrain. *Pharmacoepidemiol Drug Saf*. 2001;10: 219-227.
- 457 39. AlDrabah E, Irshaid Y, Yasein N, Zmeili S. Prescription pattern of antihypertensive drugs in Family
458 Practice Clinics at Jordan University Hospital. *Med Sci Int Med J*. 2013;2: 469.
- 459 40. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure
460 control among United States adults with hypertension: the National Health And Nutrition Examination Survey,
461 2001 to 2010. *Circulation*. 2012 Oct 23;126(17):2105-14. doi: 10.1161/CIRCULATIONAHA.112.096156.
462 PMID: 23091084.
- 463 41. Moser, M. (1998). The cost of treating hypertension can we keep it under control without
464 compromising the level of care?. *American Journal Of Hypertension*, 11(3), 120S-127S.
465 [https://doi.org/10.1016/s0895-7061\(98\)00106-x](https://doi.org/10.1016/s0895-7061(98)00106-x)
- 466 42. Cameron A, Mantel-Teeuwisse AK, Leufkens HG, Laing RO. Switching from originator brand
467 medicines to generic equivalents in selected developing countries: how much could be saved? *Value Health*.
468 2012;15: 664-673.
- 469 43. AL-Kanderi BM, AL-Otaibi M, AL-Abdulghani K.Limited Availability of Anti-Hypertensive
470 Medications in Primary Care in Kuwait. *Electron J Gen Med*. 2009;6.

471
472
473
474
475
476

Appendix

Table 11: Substituted hypertension drugs

Brand Name of drug	Generic (scientific) name of drug	
Adalat LA 30	Nefidipine	477
Aldactone 25 & 100	Spirolactone	478
Aldomet 250 & 500	Methyldopa	479
Capoten 25 & 50	Captopril	480
Concor 5	Bisoprolol	481
Esidrex	Hydrochlorothiazide	482
Inderal 10 & 40	Propranolol	483
Isoptin 80 & SR 240	Verapamil	484
Istin 10	Amlodipine	485
Lasix	Furosemide	486
Lopresor 100	Metoprolol	487
Norvasc	Amlodipine	488
Tenol 50 & 100	Atenolol	489
Tenolol 50	Atenolol	490
Tenormin 50 & 100	Atenolol	491
Zestoretic	Lisinopril/Hydrochlorothiazide	492
Zestril 5, 10, 15 and 20	Lisinopril	493
Cozaar 50	Losartan	494

497

498
499
500
501
502

Table 12: Unsubstituted hypertension drugs.

Brand Name of drug	Generic (scientific) name of drug
Atacand 8 &16	Candesartan
Co-diovan 80/12.5 & 160/12.5	Valsartan/Hydrochlorothiazide
Concor 2.5 & 10	Bisoprolol
Coversyl 4 & 5 & 10	Perindopril
Diovan 80 & 160	Valsartan
Exforge 10/160	Amlodipine/Valsartan
Exforge HCT 10/160/12.5	Amlodipine/Valsartan/Hydrochlorothiazide
Lercadip 10	Lercadipine
Lopresor 50	Metoprolol
Micardis 40 &80	Telmisartan
Micardis plus 40/12.5	Telmisartan/Hydrochlorothiazide
Minipress 2	Prazosin
Moduretic	Amiloride HCl/Hydrochlorothiazide
Natrilix SR 1.5	Indapamide
Physiotens 0.2 & 0.4	Moxonidine
Tenoretic	Atenolol/Chlorthalidone
Triplixam	Perindopril/Indapamide/amlodipine
Inhibace	Cilazapril
Atelec	Cilndipine

503